APC Anti-Mouse CD8a (53-6.7)
| Cat No. | Size | Price | Quantity | |
|---|---|---|---|---|
| 20-0081-U025 | 25 µg | $30.00 | ||
| 20-0081-U100 | 100 µg | $90.00 |
Technical Data Sheet
View All Formats
Request Custom/BulkDescription
The 53-6.7 antibody reacts with the 32-34 kDa alpha subunit of mouse CD8, known as CD8a or CD8 alpha. CD8a can form a homodimer (CD8 alpha-alpha), but is more commonly expressed as a heterodimer with a second chain known as CD8b or CD8 beta. CD8 acts as a co-receptor in antigen recognition and subsequent T cell activation that is initiated upon binding of the T cell receptor (TCR) to antigen-bearing MHC Class I molecules. The cytoplasmic domains of CD8 provide binding sites for the tyrosine kinase lck, facilitating intracellular signaling events that lead to T cell activation, development, and cytotoxic effector functions. CD8+ cytotoxic T cells (CTLs) play an important role in inducing cell death of tumor cells, as well as cells infected by virus, bacteria or parasites.
The 53-6.7 antibody is widely used as a phenotypic marker for mouse CD8a expression on cytotoxic T cells, thymocytes, as well as on certain cell types that do not also express the TCR, including some NK cells and lymphoid dendritic cells.
Recent Publications:
Ishida Y, Kuninaka Y, Nosaka M, et al. Prevention of CaCl2-induced aortic inflammation and subsequent aneurysm formation by the CCL3-CCR5 axis. Nat Commun. 2020 Nov 25;11(1):5994. doi: 10.1038/s41467-020-19763-0. PMID: 33239616.
The 53-6.7 antibody reacts with the 32-34 kDa alpha subunit of mouse CD8, known as CD8a or CD8 alpha. CD8a can form a homodimer (CD8 alpha-alpha), but is more commonly expressed as a heterodimer with a second chain known as CD8b or CD8 beta. CD8 acts as a co-receptor in antigen recognition and subsequent T cell activation that is initiated upon binding of the T cell receptor (TCR) to antigen-bearing MHC Class I molecules. The cytoplasmic domains of CD8 provide binding sites for the tyrosine kinase lck, facilitating intracellular signaling events that lead to T cell activation, development, and cytotoxic effector functions. CD8+ cytotoxic T cells (CTLs) play an important role in inducing cell death of tumor cells, as well as cells infected by virus, bacteria or parasites.
The 53-6.7 antibody is widely used as a phenotypic marker for mouse CD8a expression on cytotoxic T cells, thymocytes, as well as on certain cell types that do not also express the TCR, including some NK cells and lymphoid dendritic cells.
Recent Publications:
Ishida Y, Kuninaka Y, Nosaka M, et al. Prevention of CaCl2-induced aortic inflammation and subsequent aneurysm formation by the CCL3-CCR5 axis. Nat Commun. 2020 Nov 25;11(1):5994. doi: 10.1038/s41467-020-19763-0. PMID: 33239616.
Product Details
| Name | APC Anti-Mouse CD8a (53-6.7) |
|---|---|
| Cat. No. | 20-0081 |
| Alternative Names | CD8 alpha, Ly-2, Ly-35, Ly-B, Lyt-2 |
| Gene ID | 12525 |
| Clone | 53-6.7 |
| Isotype | Rat IgG2a, κ |
| Reactivity | Mouse |
| Cross Reactivity | |
| Format | APC |
| Application | Flow Cytometry |
| Citations* |
Rita Kansal, Noah Richardson, Indira Neeli, Saleem Khawaja, Damian Chamberlain, Marium Ghani, Qurat-ul-ain Ghani, Louisa Balazs, Sarka Beranova-Giorgianni, Francesco Giorgianni, James N. Kochenderfer, Tony Marion, Lorraine M. Albritton, Marko Radic. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019 Mar 6;11(482). pii: eaav1648. doi: 10.1126/scitranslmed.aav1648 Shimada K, Porritt RA, Markman JL, et al. T-Cell-Intrinsic Receptor Interacting Protein 2 Regulates Pathogenic T Helper 17 Cell Differentiation. Immunity. 2018;49(5):873-885.e7. doi:10.1016/j.immuni.2018.08.022. Willinger T and Flavell RA. 2012. Proc. Natl. Acad. Sci. 109:8670-8675. (Flow cytometry) Thaventhiran JED, Hoffmann A, Magiera L, de la Roche M, Lingel H, Brunner-Weinzierl M, and Fearon DT. 2012. Proc. Natl. Acad. Sci. 10.1073. (Immunohistochemistry – OCT embedded frozen tissue) Mochimaru H, Usui T, Yaguchi T, Nagahama Y, Hasegawa G, Usui Y, Shimmura S, Tsubota K, Amano S, Kawakami Y, and Ishida S. 2008. Invest. Ophthalmol. Vis. Sci. 49(5):2172-2127. (in vivo cell depletion) Fan K, Zhou M, Pathak MK, Lindner DJ, Altuntas CZ, Touhy VK, Borden EC, and Yi T. 2005. J. Immunol. 175:7003-7008. (Immunohistochemistry – frozen tissue) Nutt SL, Metcalf D, D’Amico A, Polli M, and Wu L. 2005. J. Exp. Med. 201:221-231. (Immunomagnetic bead depletion) Fan G-C, and Singh, RR. 2002. J. Exp. Med. 196: 731-741. (in vitro cell depletion) Bosselut R, Zhang W, Ashe JM, Kopacz JL, Samelson LE, and Singer A. 1999. J. Exp. Med. 190: 1517-1526. (Immunoprecipitation) |
FC = Flow Cytometry; FA = Functional Assays; ELISA = Enzyme-Linked Immunosorbent Assay; ICC = Immunocytochemistry; IF = Immunofluorescence Microscopy; IHC = Immunohistochemistry; IHC-F = Immunohistochemistry, Frozen Tissue; IHC-P = Immunohistochemistry, Paraffin-Embedded Tissue; IP = Immunoprecipitation; WB = Western Blot; EM = Electron Microscopy
*Tonbo Biosciences tests all antibodies by flow cytometry. Citations are provided as a resource for additional applications that have not been validated by Tonbo Biosciences. Please choose the appropriate format for each application and consult the Materials and Methods section for additional details about the use of any product in these publications.